-
UK Mesothelioma Victim Files Suit Against Sir Richard Branson
A 74-year-old former shop fitter from the United Kingdom has filed a mesothelioma lawsuit against Sir Richard Branson, the billionaire and former owner of Virgin Records. According to the claim, Bernard Jones had worked on the first retail space for the iconic record store and was exposed to asbestos while doing demolition and installation work.
-
Testimony in Asbestos Lawsuit Reveals the Pain and Grief of Mesothelioma
Mesothelioma lawsuits tend to focus on how the victim was exposed to asbestos and whether enough of the carcinogen was present to have led to their fatal illness. But testimony heard yesterday via Zoom made clear that the real issue at the heart of each case is the pain and loss faced by every family
-
Study Confirms Positive Effects of Mesothelioma Surgery After Radiotherapy
Finding the right treatment protocol for the treatment of malignant pleural mesothelioma is an ongoing project, with researchers around the world working diligently to identify the correct combination of treatments, in the right order, to deliver the best overall survival. A recent study published in the renowned journal The Lancet Oncology has revealed that patients undergoing the most
-
Finnish Researchers Identify Characteristics of Long-Term Mesothelioma Survivors
Malignant pleural mesothelioma is a rare and aggressive form of cancer that combines a remarkably long latency period with a short survival time once diagnosed. Decades go by between patients being exposed to asbestos and first manifesting symptoms, yet once patients start to feel sick they usually die in less than two years, sometimes in
-
Second-Hand Mesothelioma Lawsuit Allowed to Proceed Despite Asbestos Company Argument
Exposure to asbestos can lead to a wide range of deadly diseases, including malignant mesothelioma, and that exposure does not need to be direct. According to a lawsuit filed by Lorraine Sprague, not only did asbestos cause the lung cancer that killed her husband David back in 2003, but now it has led to her
-
Study Reveals Concerning Gender Disparities in Mesothelioma Treatment
According to a recent study conducted by physicians at the University of Pennsylvania’s Perelman School of Medicine, mesothelioma is not an equal opportunity disease in terms of either its prevalence or in the way that physicians provide treatment. Publishing their findings in the journal Clinical Lung Cancer, the study’s authors determined that women diagnosed with mesothelioma
-
21-Month Follow-Up Data for Mesothelioma Drug Indicates Long-Term Survival
Just days after being granted FastTrack status by the U.S. Food and Drug Administration, Targovax released the latest clinical data for ONCOS-102, revealing continued overall survival that has not yet reached an apparent median point.
-
Navy Vet Gets More Time to Collect Evidence in Mesothelioma Case
The United States District Court in Tacoma, Washington has granted a Navy veteran diagnosed with mesothelioma more time to establish the facts in his personal injury lawsuit, despite the objections of the asbestos company he is accusing of negligence. Though Meriden Molded Plastic tried to have the case against them dismissed for lack of evidence
-
19-Year Survival Seen in Innovative Treatment of Peritoneal Mesothelioma
Dr. Paul Sugarbaker is one of the nation’s leading mesothelioma surgeons, so when he calls a study’s results impressive, people take notice. He recently authored a report detailing positive outcomes seen from a new protocol for peritoneal mesothelioma: The patients involved in the study have lived as long as 19 years with the treatment.
-
Immunotherapy Drug Receives Fast-Track Designation for Mesothelioma Treatment
The U.S. Food and Drug Administration has created several unique incentives for companies that develop treatments for rare or intractable diseases like malignant mesothelioma. These incentives, which include market exclusivity or expedited movement through the drug approval process, are offered in part because the audience for these drugs is so small that the drugs offer
-
Baylor Professor Receives $2.5 Million Grant for Mesothelioma Study
A professor seeking biological markers predictive of mesothelioma response to immunotherapy has been granted a $2.5 million research award to help him pursue his studies. Dr. Bryan Burt, Associate Professor of Surgery and Chief of the Division of General Thoracic Surgery at Baylor College of Medicine was recently notified that he will be receiving a five-year
-
Railroad Bridge Operator Blames Maine Central Railroad for His Mesothelioma
The question of who is responsible for an individual’s exposure to asbestos is at the heart of every mesothelioma lawsuit. Each case is a little different, with most involving individuals accusing asbestos product companies of placing profits over people in their failure to warn of the hazards hidden within the items they sold or manufactured.
-
UK Mesothelioma Victim Recounts Success with Experimental Treatment
Recent reports revealed that a combination of Nivolumab and Ipilimumab immunotherapy treatments showed significant success in extending overall survival in patients diagnosed with malignant mesothelioma. But there’s nothing quite like hearing the outcome directly from a patient like 69-year-old Michael Conway, who was part of the clinical trial. Speaking to his local newspaper in Milton
-
UK Study Reveals Mesothelioma’s Unique Psychological Impact
It is easy to understand that mesothelioma victims and their families experience a rollercoaster of emotions, but a recently published study by researchers in the United Kingdom has provided a window into the profound and unique sense of loss, grief, anxiety and isolation that they feel.
-
Pandemic Fears Lead to Delays in Diagnosis of Mesothelioma and Other Cancers
Malignant mesothelioma is a rare form of cancer that is always considered fatal. Effective treatment is complicated by a long latency period and symptoms not appearing until late in the cancer’s progression. While this has long been a concern, experts say that the situation has been made far worse by COVID-19 as those who are
-
Mesothelioma Patients and the COVID-19 Vaccine
As the COVID-19 vaccine is being rolled out across the United States, patients diagnosed with malignant mesothelioma and other cancers are finding themselves uncertain about what they should do. Not only are they unclear regarding whether they should be vaccinated, but once told that they should they are having a hard time getting access to
-
Navy Veteran’s Family Blames Mesothelioma Death on Gasket Manufacturer
There was a painfully brief period between when Navy veteran Donald Johnson was told he had malignant mesothelioma and when he succumbed to the disease: Mr. Johnson got confirmation of his diagnosis on July 17th, 2018 and died just one month later, on August 22nd. Though he died too quickly to provide his own testimony
-
Mesothelioma Researcher Speaks to Need for Further Clinical Trials
Speaking at the 18th Annual Winter Lung Cancer Conference, noted mesothelioma researcher Anne S. Tsao, MD told the virtual gathering of physicians that recent advances in the frontline treatment of malignant mesothelioma have made clear the need for further clinical trials evaluating optimal sequencing of checkpoint inhibitors for patients in the salvage setting, as well as
-
Mesothelioma Advocates Cheered by NJ Supreme Court Decision in Talcum Powder Asbestos Case
Asbestos in talcum powder has been blamed for a growing number of malignant mesothelioma and ovarian cancer diagnoses, and victims are coming forward to seek justice from those responsible. Two New Jersey women who filed an asbestos lawsuit against Johnson & Johnson in 2014 had faced disappointment when a trial judge sided with the consumer
-
Study Reveals Benefits of Carboplatin Use in Treating Malignant Mesothelioma
Carboplatin and cisplatin are both platinum-based chemotherapy drugs used in the treatment of malignant mesothelioma, but there has long been debate on which is the best option for patients. While cisplatin has been associated with better overall survival, it imposes uncomfortable side effects that reduce patient quality of life. By contrast, carboplatin causes fewer adverse
